trending Market Intelligence /marketintelligence/en/news-insights/trending/1i9WqILpMpC8uMuXCnDwYA2 content esgSubNav
In This List

ACADIA Pharmaceuticals, Siegfried sign manufacturing agreement

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

ACADIA Pharmaceuticals, Siegfried sign manufacturing agreement

ACADIA Pharmaceuticals Inc.'s Swiss subsidiary ACADIA Pharmaceuticals GmbH entered into a manufacturing agreement under which Siegfried Holding AG will supply pimavanserin tartrate, the active ingredient of ACADIA's Nuplazid drug.

ACADIA said in a Form 8-K filing that it will purchase a specified percentage of pimavanserin tartrate for its U.S. and European markets. The five-year contract will renew automatically for an additional two-year term unless either party terminates or decides not to renew the agreement.

The deal replaces an August 2015 cooperation agreement and product schedule between ACADIA GmbH and Siegfried Evionnaz SA.

San Diego-based ACADIA develops and markets therapies for central nervous system disorders. Nuplazid is used in the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Switzerland-based Siegfried develops active pharmaceutical ingredients for other companies.